Deep brain stimulation in patients with mixed movement disorders linked to ADCY5
GPi-DBS can be considered as a relevant therapeutic option for MxMD-ADCY5 in case of pharmacological treatment failure both in patients with chronic motor impairment and those with paroxysmal exacerbations meeting criteria for SAME. Given the response to DBS in the two groups of patients, it is plausible that MxMD-ADCY5 reflects basal ganglia dysfunction mediated by dysregulated cAMP signalling, and that DBS acts by restoring homeostatic inhibitory control in these circuits.
Authors
- M.-A. L. Spitz
- N. Dorison
- C. Ravelli
- J. Baik
- P. Vayssière
- C. Nilles
- M.-C. François-Heude
- E. Retailleau
- E. Chauvet-Piat
- E. Conabady
- O. Trouillard
- C. Desjardins
- G. Poulen
- A. Roubertie
- E. Roze
- C. Dubacq
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Sorbonne Université (FR)
- Hôpital Armand-Trousseau (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Hôpital Beau-Séjour (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- Fondation Ophtalmologique Adolphe de Rothschild (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Institut du Cerveau (FR)
- Hôpital Civil, Strasbourg (FR)
Publication Details
- Journal
- Revue Neurologique
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1016/j.neurol.2025.12.003
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00